share_log

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

诺瓦瓦克斯医药 | 8-K：2024年股东大会会议决议公告
美股sec公告 ·  06/14 16:07
Moomoo AI 已提取核心信息
On June 13, 2024, Novavax, Inc. held its Annual Meeting where several key proposals were voted upon by stockholders. The stockholders approved the amendment and restatement of the Amended and Restated 2015 Stock Incentive Plan, which will increase the available shares for issuance by 6,500,000. Additionally, the 2013 Employee Stock Purchase Plan was amended and restated to increase the available shares by 1,000,000. The stockholders also elected three Class II directors to serve a three-year term, approved the executive compensation for 2023, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposals were detailed in the 2024 Proxy Statement filed with the SEC on April 29, 2024, and amended on June 5, 2024. The full text of the amended plans is incorporated into the Current Report on Form 8-K as exhibits.
On June 13, 2024, Novavax, Inc. held its Annual Meeting where several key proposals were voted upon by stockholders. The stockholders approved the amendment and restatement of the Amended and Restated 2015 Stock Incentive Plan, which will increase the available shares for issuance by 6,500,000. Additionally, the 2013 Employee Stock Purchase Plan was amended and restated to increase the available shares by 1,000,000. The stockholders also elected three Class II directors to serve a three-year term, approved the executive compensation for 2023, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposals were detailed in the 2024 Proxy Statement filed with the SEC on April 29, 2024, and amended on June 5, 2024. The full text of the amended plans is incorporated into the Current Report on Form 8-K as exhibits.
2024年6月13日，Novavax公司举行年度股东大会，股东们对几项关键提案进行了投票表决。股东批准修订并重申2015年经修订的股票激励计划，将增加可发行股票数量650万股。此外，2013年职工购股计划也经修订并重申，可发行股票数量增加了100万股。股东还选出三名二类董事来担任为期三年的任期，批准2023年的高级管理人员报酬，并核准Ernst & Young LLP为截至2024年12月31日的财年独立注册公共会计师事务所。这些提案的细节已经在2024年4月29日向SEC提交的代理声明中详述，并在2024年6月5日进行了修订。修订计划的全文已被纳入提交的8-K表格的展示部分。
2024年6月13日，Novavax公司举行年度股东大会，股东们对几项关键提案进行了投票表决。股东批准修订并重申2015年经修订的股票激励计划，将增加可发行股票数量650万股。此外，2013年职工购股计划也经修订并重申，可发行股票数量增加了100万股。股东还选出三名二类董事来担任为期三年的任期，批准2023年的高级管理人员报酬，并核准Ernst & Young LLP为截至2024年12月31日的财年独立注册公共会计师事务所。这些提案的细节已经在2024年4月29日向SEC提交的代理声明中详述，并在2024年6月5日进行了修订。修订计划的全文已被纳入提交的8-K表格的展示部分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息